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A B S T R A C T   
Background and purpose: The more localized dose deposition of proton therapy (PT) compared to photon therapy 
might allow a reduction in treatment-related side effects but induces additional challenges to address. The aim of 
this study was to evaluate the impact of interfractional motion on the target and organs at risk (OARs) in cervical 
cancer patients treated with spot scanning PT using an internal target volume (ITV) strategy. 
Methods and materials: For ten locally advanced cervical cancer patients, empty and full bladder planning 
computed tomography (pCT) as well as 25 daily cone beam CTs (CBCTs) were available. The Clinical Target 
Volume (CTV), the High Risk CTV (CTVHR) (gross tumor volume and whole cervix), the non-involved uterus as 
well as the OARs (bowel, bladder and rectum) were contoured on the daily CBCTs and transferred to the pCT 
through rigid bony match. Using synthetic CTs derived from pCTs, four-beam spot scanning PT plans were 
generated to target the patient-specific ITV with 45 Gy(RBE) in 25 fractions. This structure was defined based on 
pre-treatment MRI and CT to anticipate potential target motion throughout the treatment. D98% of the targets 
and V40Gy(RBE) of the OARs were extracted from the daily anatomies, accumulated and analyzed. In addition, 
the impact of bladder volume deviations from planning values on target and bowel dose was investigated. 
Results: The ITV strategy ensured a total accumulated dose >42.75 Gy(RBE) to the CTVHR for all ten patients. 
Two patients with large bladder-related uterus motion had accumulated dose to the non-involved uterus of 35.7 
Gy(RBE) and 41.1 Gy(RBE). Variations in bowel V40Gy(RBE) were found to be correlated (Pearson r = − 0.55; p- 
value <0.0001) with changes in bladder volume during treatment. 
Conclusion: The ITV concept ensured adequate dose to the CTVHR, but was insufficient for the non-involved 
uterus of patients subject to large target interfractional motion. CBCT monitoring and occasional replanning is 
recommended along the same lines as with photon radiotherapy in cervical cancer.   
1. Introduction 
Using the characteristic Bragg peak, PT enables more localized dose 
deposition than photon therapy, and allows for additional sparing of 
healthy tissue and organs at risk (OARs) surrounding the target. The 
advantages of protons compared to photons have been shown in plan-
ning studies, which found that protons significantly reduced dose to the 
OARs [1–3]. Higher doses and larger irradiated volumes of the OARs are 
in general correlated with increased prevalence and grade of toxicity 
[4,5]. Therefore, substituting photons by protons for the External Beam 
Radiation Therapy (EBRT) phase of the treatment of locally advanced 
cervical cancer may allow patients to benefit from a lower prevalence of 
side effects. 
However, before initiating PT for gynecological malignancies, some 
challenges need to be addressed. In particular, the impact of un-
certainties related to density variations and/or organ motion needs to be 
evaluated and potentially mitigated [6,7]. With regard to organ motion, 
around one out of five cervical cancer patients experience substantial 
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interfraction movement of the uterus, mainly depending on variable 
bladder and rectum filling [8,9]. Bladder and rectum volume variations 
during the radiotherapy course have previously been found to cause 
suboptimal target coverage in cervical cancer patients [9,10]. This 
target under-dosage may even be accentuated when PT and in particular 
spot scanning is used because of the steeper dose gradients obtained. 
In photon therapy, a conventional strategy to mitigate the impact of 
interfraction motion is the use of ITV margins which are often defined 
based on pre-treatment imaging with the aim of including the most 
likely positions of the primary target during the treatment. Adaptive RT, 
by means of offline or online re-planning [11,12] modifies initial 
treatment plan parameters throughout the treatment to provide an 
optimized dose. Adaptive strategies have been proposed for pelvic ma-
lignancies in order to achieve with a limited treated volume an adequate 
target coverage despite interfractional motion [2,13–15]. Van de Schoot 
et al. [2] demonstrated the feasibility of an adaptive plan library strat-
egy for cervical cancer patients with PT and showed its superiority over 
a similar approach with photons. Busch et al. demonstrated that on-line 
dose-guided PT better accounts for large interfractional organ motion in 
the pelvis than image guided PT [12]. ITV strategies can also be com-
bined with adaptive replanning as demonstrated by Jensen et al. [16] 
with a CBCT monitoring strategy in photon radiotherapy. Furthermore, 
a recent study by Gort et al. [17] compared the robustness of ITV-based 
treatment plans with Pencil Beam Scanning PT (PBS-PT) and photon 
therapy. Based on the analysis of repeat CT scans they found PT to be 
equally robust to photons, in addition to significantly reducing the OARs 
doses. This study was based on simulations in weekly CBCT scans for 
twelve patients. 
The purpose of our study was to validate, in an independent patient 
cohort, the findings of previous studies that an ITV approach can be used 
with spot scanning PT to compensate for interfractional anatomical 
variations occurring during the whole radiotherapy course. This purpose 
was addressed by quantifying the total accumulated dose on targets and 
OARs based on daily CBCTs acquired throughout 25 fractions of 
radiotherapy. 
2. Materials and methods 
2.1. Patient data 
In this study, a data set of ten locally advanced cervical cancer pa-
tients previously treated with photons was utilized. Our cohort consisted 
in a retrospective planning study with fully anonymity, which is why 
neither Institutional Review Boards review nor patient consent was 
required according to local regulations. For each patient the following 
images were available: two CT scans in treatment position (empty and 
full bladder), pre-treatment magnetic resonance (MR) scan in treatment 
position, as well as 25 on-board acquired CBCT scans, which were used 
to position the patient prior to each fraction. EBRT was administered to 
all patients with a prescribed dose of 45 Gy in 25 fractions to the target 
related to the primary tumor and the elective lymph nodes. Three pa-
tients received a simultaneously integrated boost of 55 Gy to metastatic 
lymph nodes. All patients were contoured according to the EMBRACE II 
guidelines [18]. 
2.2. Treatment planning 
The CT numbers of CBCT scans do not accurately predict the relative 
stopping power ratios for proton dose calculation. In order to compen-
sate for this, synthetic CTs (sCTs) were generated based on information 
from the CBCT scans and the pCTs. For each patient, two sCTs were 
created: one for planning purposes, reflecting the anatomy of the patient 
on the full bladder pCT. In addition, a sCT was generated to reflect the 
anatomy of the patient at each fraction and extract fractional dose pa-
rameters. The sCTs were generated by taking the full bladder pCT outer 
body contour which was filled with water CT numbers, except for bones, 
which kept their original CT values. In addition, as shown in Fig. 1 
(right), the primary CTVs and bladder contours taken from the CBCT 
scans were filled with their corresponding CT numbers from the full 
bladder pCT. The use of sCTs ensured that no uncertainties other than 
interfractional motion of the pelvic organs influenced our study. As 
such, interfractional density variations were not included in the anal-
ysis. This approach was chosen in order to study one particular aspect of 
the problem, i.e. interfractional internal organ motion and not diluting 
the findings with other effects. An example of cervix-uterus interfraction 
motion is shown in Fig. 1 as well as a planned dose distribution for 
comparison. 
The simulations were performed using a generic machine in the 
proton Eclipse treatment planning system (v 13.7, Varian Medical Sys-
tems, Palo Alto, USA) as a representation of a Varian ProBeam spot 
scanning system. A four-beam configuration was used: two lateral 
opposed and two posterior oblique (90◦, 150◦, 210◦, and 270◦) with 
multi-field optimization (MFO). The contribution of each field to the 
total dose was not constrained. The same ITV target volume as the one 
defined for the clinical photon plans was utilized, and a plan was opti-
mized on the planning sCTs to the same dose prescription as for photon 
treatment with the assumption of Relative Biological Effectiveness 
(RBE) of 1.1. The beam parameters of the resulting plans were thereafter 
applied on the sCTs and the dose recalculated for all treatment fractions 
with their respective OARs from CBCTs. 
The target volumes related to the primary tumor were identified on 
MRI and included: gross tumor volume (GTV-T), CTVHR (GTV-T plus 
whole cervix), and low risk CTV (CTVLR) (CTVHR, whole uterus, whole 
parametria, upper vagina, and a margin towards bladder and rectum). 
For the purpose of this study, the non-involved uterus CTV (CTVuter-
us_noninv) was contoured on MRI. Radiation oncologists contoured the 
ITV from the CTVLR based on current clinical practice according to the 
EMBRACE II protocol [18]: the ITV related to the primary tumor (ITV-T) 
accounts for cervix-uterus motion expected throughout the treatment 
[19]. The ITV margin was determined individually for each patient ac-
cording to rectal filling and from the location of the CTVLR on full/empty 
bladder treatment planning CT scans as well as on the MRI which was 
also acquired in treatment planning position. The full/empty bladder 
CTs were fused with MRI based on bony structures. The ITV was con-
structed according to the physician’s expectations of motion during 
treatment, e.g. additional ITV margin was added in the posterior di-
rection in case rectum was not empty on the planning scan, as it may 
appear empty during EBRT. The construction of the ITV is described in 
more detail in Jensen et al. [16] as well as in the EMBRACE II protocol 
[18]. An elective nodal CTV (CTV-E) was also delineated. The so-called 
ITV45 was then composed of the CTV-E and the ITV-T. The planning 
target volume (PTV) was obtained by adding a 5 mm isotropic margin to 
the ITV45. 
On each CBCT the combined CTVHR and uterus, bladder, bowel and 
rectum were contoured by radiation oncologists. As the volume of the 
GTV shrinks in response to the treatment, the CTVHR becomes smaller, 
whereas the non-involved uterus region is not normally changing in 
volume. Using the assumption that the length of the non-involved uterus 
is stable in relation to the most distal fundus, we measured this distance 
on the pre-treatment MRI to delineate the non-involved uterus on all 
CBCTs. All CBCT contours, reflecting the anatomical location of the 
target and OARs just prior to the dose delivery were propagated to the 
sCTs using a rigid bony match used in clinical practice. 
2.3. Plan evaluation 
The CTVHR is a region sensitive to dose degradation as it could reduce 
local control [20] and according to EMBRACE II, a minimum of 95% of 
the prescribed dose was considered as threshold for an acceptable dose, 
i.e. 42.75 Gy (RBE). For the non-involved uterus, 40 Gy (RBE) was 
considered as threshold for acceptable dose, since the non-involved 
uterus is associated with lower risk of recurrence (microscopic spread) 
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and since a typical brachytherapy dose contribution of 5–10 Gy brings 
the total dose to the uterine body above >45 Gy (RBE) [21]. 
Dose-volume histogram (DVH) parameters were extracted from sCTs 
for all the targets which were propagated from the daily CBCTs: CTVHR, 
CTVuterus_noninv. Accumulated D98% was estimated for each patient by 
averaging D98% across all treatment fractions (DVH addition). Esti-
mation of accumulated dose through DVH addition can be considered as 
a worst-case scenario, when considering hot spots and cold spots (e.g. 
D98%) [22]. The accumulated target D98% was compared to the plan-
ned values. In addition, relative bladder V40Gy (RBE) was extracted for 
all patients on the daily sCTs. 
In order to investigate how variations in bladder volume impact the 
target dose degradation, the change in bladder volume between CBCTs 
and pCTs was calculated for all fractions of the ten patients and related 
to the target dose degradation. Furthermore, daily bowel V40Gy (RBE) 
and V30Gy (RBE) in cm3 were extracted and related to bladder volume 
change from planning CT, and Pearson’s correlation coefficients were 
calculated. 
3. Results 
The average planned D98% was 43.9 ± 0.3 Gy (RBE) for the CTVHR 
and 43.8 ± 0.3 Gy (RBE) for the CTVuterus_noninv. Planned dose to the 
OARs can be found in Supplementary Table S1. 
For all ten patients, the minimum accumulated CTVHR D98% was 
43.0 Gy (RBE) which in all cases met the 42.75 Gy (RBE) dose threshold 
(95%). As shown in Supplementary Table S2, the accumulated D98% to 
the CTVuterus_noninv was >40 Gy (RBE) (90% of prescribed dose) and 
>42.75 Gy (RBE) (95% of prescribed dose) in 9/10 and 8/10 patients, 
respectively. In the two patients receiving less than 95% of prescribed 
dose, the D98% was 35.7 Gy (RBE) (79%) and 41.1 Gy (RBE) (91%) to 
the CTVuterus_noninv and 36.5 Gy (RBE) (81% of prescribed dose) and 
41.9 Gy (RBE) (93% of prescribed dose) to the CTV, respectively. 
The distribution of the D98% for all individual fractions is illustrated 
in Fig. 2 for all ten patients. For the two patients (patient 5 and 8) with 
suboptimal coverage on the CTV, the CTVHR D98% was >42.75 Gy 
(RBE) for all fractions but one in both patients, whereas the CTVuter-
us_noninv, D98% was <40 Gy (RBE) in six fractions for the first patient and 
seven fractions for the second patient. As illustrated in Fig. 2, for a third 
patient (patient 9), the D98% of the CTVuterus_noninv was <40 Gy (RBE) in 
two fractions. It can be noticed that for the two patients that were 
subject to major interfractional motion (patient 5 and patient 8), the 
daily bladder volumes were repeatedly smaller than at planning. The 
fractions in which they experienced major dose degradation all corre-
sponded to bladders smaller by 120–300 cm3 compared to pCT (Fig. 3 
panel B and panel C). The opposite pattern was observed for patient 9 
who had minor dose degradations in two fractions on the non-involved 
uterus (Fig. 3 panel C). The bladder volume of the fractions in question 
exceeded the value on pCT by 180–200 cm3. This difference in volume 
pushed the fundus towards the superior-posterior direction and outside 
the D98% isodose. As seen on Fig. 3, several patients experienced similar 
bladder volume variations that did not induce target dose degradation. 
This is particularly the case for patient 10 who had 20 fractions deliv-
ered with a bladder smaller than on pCT by − 265 cm3 and up to − 307 
cm3. 
Variations in irradiated volume of the bowel were found to be 
correlated (r = − 0.60 and r = − 0.55 with p-value <0.0001 for V30Gy 
(RBE) and V40Gy (RBE), respectively) with changes in bladder volume 
between full bladder pCT and sCTs (Fig. 4 and Supplementary material 
Fig. S1). Two patients that were subject to major interfractional motion 
had on average higher fractional V40Gy (RBE) of the bowel compared to 
planning values (upper left corner of Fig. 4). 
The difference in bladder V40Gy (RBE) [%] between accumulated 
dose and planned dose ranged between − 13% and 3% for patients 1–9 
while it was 50% for patient 10. For this patient, the bladder volume was 
on average 275 cm3 smaller compared to the planning value. 
Fig. 1. Sagittal view of a synthetic CT for patient 8 showing the planned dose distribution on the left as well as planning target contours (ITV contour in orange, PTV 
in blue), and cervix-uterus position at fraction 7 (CTVHR in red and non-involved uterus in yellow) on the right. For this fraction, D98% was 43.1 Gy(RBE) and 2.7 Gy 
(RBE) on the CTVHR and CTVuterus_noninv. Dose colorwash indicates doses between 30 Gy[RBE] and 48.1 Gy[RBE]. (For interpretation of the references to color in this 
figure legend, the reader is referred to the web version of this article.) 
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4. Discussion 
In the present study an ITV strategy commonly used in photon 
radiotherapy practice was applied to PT and its performance in 
compensating cervix-uterus interfractional motion was evaluated. The 
study showed that the use of individualized ITV margins plus a 5 mm 
PTV margin, ensured an acceptable total accumulated dose to the CTVHR 
in all ten patients analyzed. Furthermore, the non-involved uterus, re-
gion particularly prone to interfractional motion, was sufficiently 
covered in all patients but one. 
Our results are in line with the ones of Gort et al. [17] which showed 
by analyzing repeat CT scans, that ITV-based treatment plans with PBS- 
PT and photon therapy were equally robust to interfractional motion. 
However, it is interesting to note that their worst D98% dose degrada-
tion of the uterus was of less than 30%, while in our study fractions with 
dose degradation greater than 80% was observed in one patient. Despite 
these occasional large underdosages of the uterus observed in our study, 
the CTVHR remained well covered with a total accumulated dose 
meeting the recommended constraints. Considering the pattern of 
underdosage of this patient (patient 8), the target dose could have been 
improved with a library-based plan. However, exceptionally large 
anatomical variations, as seen for this patient, illustrate the interest of 
daily online treatment adaptation. One further patient received more 
than 95% of the prescribed dose on the CTVHR, but two fractions had less 
than 40 Gy(RBE) on the CTV_uterus_noninv , which despite being tolerable 
in regard to the accumulated dose on the CTV_uterus_noninv, still would 
have benefited from one re-plan with an updated ITV for two fractions. 
Patients with suboptimal coverage illustrate the need for alternative 
approaches. Individualized ITV margins for the mobile target related to 
the primary tumor combined with a CBCT-monitoring-based offline re- 
planning may be efficient without requiring excessive resources [16]. 
A plan of the day concept as proposed by van de Schoot et al. [2] or a 
real-time re-planning strategy as reported by Jagt et al. [11] for cervix 
cancer with a prior plan-library may further improve target coverage 
and OARs sparing for patients subject to large interfractional anatomical 
variations. Nevertheless, the workflow of the latter strategy is still not 
clinically available and some challenges remain to be addressed before 
implementation of on-line adaptive RT/PT in clinical routine: improved 
image quality and automatic contouring would be required for this 
approach to become feasible and cost-effective [23,24]. 
Consistent with several studies [8,9] on photon therapy, our results 
indicated the need of a bladder filling protocol during treatment. Our 
study showed that large differences in bladder volume between the day 
of planning and the delivery could cause target dose degradation as well 
as bowel dose deviations compared to planned values. The largest 
overdosage of the bowel was found for bladders that were smaller during 
dose delivery compared to pCT. This indicates, similarly to what was 
demonstrated in conventional photon therapy [16] that large bladder 
volumes achieved on the day of planning CT acquisition and difficult to 
reproduce on the day of dose delivery can induce higher dose to the 
bowel than expected at planning. 
Robust optimization, such as the worst-case algorithm, is designed to 
anticipate the impact of patient positioning errors and range un-
certainties on the proton beams and is currently seen as a standard 
requirement in PT. In a real scenario in which all sources of uncertainty 
disregarded in the present study, combine, such a planning strategy, 
robust to density changes and patient shifts would lead to improved 
delivered doses to the patients. 
The results of planning studies evaluating the impact of uncertainties 
for a specific modality depend on several parameters, which for protons 
would include the beam configuration and plan optimization. The beam 
configuration chosen in the present study (two lateral opposed and two 
posterior oblique) places the distal fall off region, associated with the 
steepest dose gradient, mainly in the anterior part of the patient. This 
arrangement was chosen, in order for the beams not to pass through the 
bowels hence minimizing the irradiation of this organ as well as the 
likelihood of crossing gas pockets. As the pCT was aimed to be acquired 
with a full bladder, the patients subject to bladder-filling induced uterus 
motion would likely experience it with emptier bladders, inducing an 
anterior-inferior displacement of the fundus, towards the low dose re-
gion. Therefore, beam configurations associated with shallower dose 
gradients in the anterior part of the patient could have reduced the dose 
Fig. 2. Boxplots showing D98% Gy (RBE) on CTVHR and CTVuterus_noninv across all fractions for the ten patients studied. The bottom edge, the central mark and the 
top edge of the box indicate the 25th, the 50th and 75th percentiles, respectively. The blue asterisks show the total accumulated D98%. (For interpretation of the 
references to color in this figure legend, the reader is referred to the web version of this article.) 
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Fig. 3. Target D98% (Gy RBE) relative to planned dose (sCT/pCT) as a function of bladder volume difference (Panel A: CTVHR, Panel B: CTV, Panel C: 
CTV_uterus_noninv). 
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degradations observed in this study. 
The relatively small number of patients is a clear limitation of this 
study, since it is not representative of the whole cervical cancer patients’ 
population. However, the analyzed cohort includes patients with occa-
sional large interfractional uterus motion and the analysis of all daily 
fractions allowed us to estimate total accumulated dose for several parts 
of the target each associated with different risk of recurrence. In addi-
tion to the dose degradation found in this study which is only due to 
interfractional target motion, additional sources of uncertainties should 
be combined and taken into account, such as interfractional density 
variations, gas cavities, body outline variations [6] stopping power ratio 
(SPR)-to-HU correspondence, set up and contouring uncertainties 
[25,26]. Berger et al. [6] showed that gas cavities and outline variations 
had minor impact on target and OARs doses. In addition, the study by 
Gort et al. [17] indicated that, with all sources of uncertainties consid-
ered, robustly optimized PBS-PT was equally robust against inter- and 
intrafraction variability compared to photon therapy and provides bet-
ter OARs sparing. 
In conclusion, our study validates that the use of individualized ITV 
margins, as proposed in the EMBRACE II protocol, ensures satisfactory 
total accumulated dose to the CTVHR for all analyzed patients despite 
occasional large interfractional displacement. Our results also highlight 
the importance of bladder filling protocols to avoid target underdosage 
or increased dose to OARs as compared to at pre-treatment planning. In 
addition, our results show the interest of alternative approaches, such as 
replanning and adaptive strategies for the patients subject to large 
interfractional motion. 
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